1. Home
  2. SRRK vs HAFN Comparison

SRRK vs HAFN Comparison

Compare SRRK & HAFN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SRRK
  • HAFN
  • Stock Information
  • Founded
  • SRRK 2012
  • HAFN 2012
  • Country
  • SRRK United States
  • HAFN Bermuda
  • Employees
  • SRRK N/A
  • HAFN N/A
  • Industry
  • SRRK Biotechnology: Biological Products (No Diagnostic Substances)
  • HAFN
  • Sector
  • SRRK Health Care
  • HAFN
  • Exchange
  • SRRK Nasdaq
  • HAFN Nasdaq
  • Market Cap
  • SRRK 2.8B
  • HAFN 3.0B
  • IPO Year
  • SRRK 2018
  • HAFN N/A
  • Fundamental
  • Price
  • SRRK $26.49
  • HAFN $5.26
  • Analyst Decision
  • SRRK Strong Buy
  • HAFN Strong Buy
  • Analyst Count
  • SRRK 7
  • HAFN 1
  • Target Price
  • SRRK $34.00
  • HAFN $10.00
  • AVG Volume (30 Days)
  • SRRK 984.5K
  • HAFN 2.1M
  • Earning Date
  • SRRK 11-12-2024
  • HAFN 01-01-0001
  • Dividend Yield
  • SRRK N/A
  • HAFN 30.73%
  • EPS Growth
  • SRRK N/A
  • HAFN N/A
  • EPS
  • SRRK N/A
  • HAFN 1.56
  • Revenue
  • SRRK N/A
  • HAFN $2,970,261,000.00
  • Revenue This Year
  • SRRK N/A
  • HAFN N/A
  • Revenue Next Year
  • SRRK N/A
  • HAFN N/A
  • P/E Ratio
  • SRRK N/A
  • HAFN $3.42
  • Revenue Growth
  • SRRK N/A
  • HAFN 18.39
  • 52 Week Low
  • SRRK $6.76
  • HAFN $5.13
  • 52 Week High
  • SRRK $35.38
  • HAFN $8.99
  • Technical
  • Relative Strength Index (RSI)
  • SRRK 50.87
  • HAFN N/A
  • Support Level
  • SRRK $25.86
  • HAFN N/A
  • Resistance Level
  • SRRK $28.11
  • HAFN N/A
  • Average True Range (ATR)
  • SRRK 1.68
  • HAFN 0.00
  • MACD
  • SRRK -0.92
  • HAFN 0.00
  • Stochastic Oscillator
  • SRRK 11.71
  • HAFN 0.00

About SRRK Scholar Rock Holding Corporation

Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.

About HAFN Hafnia Limited Common Shares

Hafnia Ltd is one of the tanker owners, transporting oil, oil products and chemicals for national and international oil companies, chemical companies, as well as trading and utility companies. As owners and operators of around 200 vessels, It offers a fully integrated shipping platform, including technical management, commercial and chartering services, pool management, and a large-scale bunker procurement desk.

Share on Social Networks: